Principal Financial Group Inc. Reduces Holdings in Thermo Fisher Scientific Inc. $TMO

Principal Financial Group Inc. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 624,721 shares of the medical research company’s stock after selling 16,889 shares during the quarter. Principal Financial Group Inc.’s holdings in Thermo Fisher Scientific were worth $307,069,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC increased its stake in Thermo Fisher Scientific by 72.3% during the first quarter. Chicago Partners Investment Group LLC now owns 1,802 shares of the medical research company’s stock worth $926,000 after acquiring an additional 756 shares during the last quarter. Parr Mcknight Wealth Management Group LLC lifted its stake in shares of Thermo Fisher Scientific by 764.8% in the 1st quarter. Parr Mcknight Wealth Management Group LLC now owns 4,471 shares of the medical research company’s stock valued at $2,198,000 after purchasing an additional 3,954 shares during the last quarter. Triglav Investments D.O.O. grew its holdings in shares of Thermo Fisher Scientific by 32.8% during the 1st quarter. Triglav Investments D.O.O. now owns 21,000 shares of the medical research company’s stock worth $10,322,000 after purchasing an additional 5,186 shares during the period. Global Assets Advisory LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth about $75,000. Finally, Trifecta Capital Advisors LLC raised its holdings in Thermo Fisher Scientific by 0.3% in the 1st quarter. Trifecta Capital Advisors LLC now owns 12,018 shares of the medical research company’s stock valued at $5,907,000 after buying an additional 38 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $534.99 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $403.36 and a 52 week high of $643.99. The company has a fifty day simple moving average of $480.57 and a two-hundred day simple moving average of $515.34. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company has a market cap of $198.81 billion, a price-to-earnings ratio of 29.41, a price-to-earnings-growth ratio of 2.34 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the firm earned $5.15 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Weiss Ratings cut shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a research report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 target price on the stock. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $602.14.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.